MarketNewsUpdates News Commentary
NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Industry insiders say that the global demand for Antimony market is expected to continue growing...
MarketNewsUpdates News Commentary
NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Industry insiders say that the global demand for Antimony market is expected to continue growing...
NAPLES, Fla., Aug. 11, 2025 /PRNewswire/ -- Prisidio, the secure digital vault company that helps individuals and families Collect, Protect, and Share their most essential...
CHICAGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Live4Lali collaborated in a volunteer initiative alongside the SBB Research Group Foundation, which partners with local nonprofits through its Champion A Charity Program.
A Free Call to 811 Will Help Keep You Safe and Avoid Expensive Repairs Averaging $3,500
OAKLAND, Calif., Aug. 8, 2025 /PRNewswire/ -- Monday, August...
Dr. Wenham is Principal investigator on Anixa's CAR-T therapy for Ovarian Cancer
SAN JOSE, Calif., Aug. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or...
VADUZ, Liechtenstein, Aug. 7, 2025 /PRNewswire/ -- Implantica AG (publ), a leading medtech company pioneering advanced implantable medical technologies, today announced the second peer-reviewed...
Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ® in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for IXCHIQ®. IXCHIQ® remains indicated in the United States for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years of age and older who are at high risk of exposure to CHIKV.
This partnership marks a pivotal step for both organizations, focusing on mutual growth and increased market footprint.
BENGALURU, India, Aug. 7, 2025 /PRNewswire/ -- iValue...